Detailed Lipid Profiles and Lipid-related Residual Risk after 12-week 10 mg Rosuvastatin Treatment for Acute Myocardial Infarction

Conclusion More than half of the Japanese AMI patients treated with rosuvastatin 10 mg/day did not achieve the guideline-recommended goal of lipid management and still had lipid-related residual risk at 12 weeks. Particular attention should be paid to patients with low baseline HDL-C levels and those without diabetes with regard to their on-treatment lipid profiles.PMID:38494714 | DOI:10.2169/internalmedicine.3476-24

Source: Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Yuki Kondo Masaru Ishida Takenori Ishisone Masanobu Niiyama Takuya Osaki Yuki Matsumoto Yuko Maegawa Kenta Sasaki Ryo Ninomiya Yuji Takahashi Yu Ishikawa Takumi Kimura Yudai Shimoda Munetaka Morikawa Hidenori Saito Tomonori Itoh Yoshihiro Morino Source Type: research